Overview

Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting

Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to implement quantitative assessment tools for the treatment of active neovascular AMD patients in a real-world setting in order to provide advantages for both patients (treatment burden) and healthcare system (scheduling visits/treatments).
Phase:
Phase 4
Details
Lead Sponsor:
Medical University of Vienna
Treatments:
Bevacizumab